A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Neoplasms
Interventions
DRUG

IPI-926

Oral daily dosing

Trial Locations (5)

21231

Johns Hopkins Uninversity, Baltimore

80045

University of Colorado Health Science Center, Aurora

85258

TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale

94063

Stanford University, Redwood City

H3T 1E2

McGill University Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY